News|Articles|August 21, 2026

FAQ: What Labs Do You Actually Need to Monitor With JAK Inhibitors?

NP/PA Connect

A practical guide to baseline testing, follow-up laboratory monitoring, and managing abnormalities in patients receiving oral JAK inhibitors.

Oral Janus kinase (JAK) inhibitors have expanded systemic treatment options for inflammatory skin diseases, offering rapid and effective disease control for appropriately selected patients. Their use, however, comes with laboratory monitoring considerations that can vary by agent, patient risk factors, and stage of treatment.

Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.